Search Follow us

RedHill Biopharma (RDHL)

Business description

RedHill Biopharma is a specialty pharma company with a broad R&D pipeline focusing on gastrointestinal and inflammatory diseases and also promotes four GI products in the US. The most advanced programs are TALICIA (RHB-105) for H. pylori infection, RHB-104 for Crohn’s disease, BEKINDA for gastroenteritis and IBS-D, and RHB-204 for NTM.

Stock data

Market cap.US$143.7m
Last closeUS$8.42
High / Low (52 weeks)US$11.3 / US$4.8
Stock market listingUS, Tel Aviv Stock Exchange
Forecast net cash (US$m)28.2
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceuticals & healthcare

Price performance

%1m3m12m
Actual22.26.637.6
Relative *12.62.439.7

* % Relative to local index

Other companies in sector Show

4SC aap Implantate
Aastrom Biosciences AB Science
Abcam Abivax SA
Ablynx Abzena
Acacia Pharma Acarix
Acerus Pharmaceuticals Achillion Pharmaceuticals
Acorda Therapeutics Actinium Pharmaceuticals
Actinogen Medical Active Biotech
Acucela Addex Therapeutics
Adherium ADL Bionatur Solutions
Adocia Advanced Medical Solutions
Aegerion Pharmaceuticals Aeterna Zentaris
AFT Pharmaceuticals Agennix
Akari Therapeutics Alchemia
Alexza Pharmaceuticals Algeta
Alimera Sciences ALK Abello
Alkermes Allergy Therapeutics
Alliance Pharma Allium Medical Solutions
Alnylam Pharmaceuticals Amarantus BioScience
Amarin Amplifon
AmpliPhi Biosciences Angle
Animalcare Group Anteo Diagnostics
Anthera Pharmaceuticals Antibe Therapeutics
Aratana Therapeutics Ardea Biosciences
Ardelyx Arena Pharmaceuticals
arGEN-X Argos Therapeutics
Ariad Pharmaceuticals Arix Bioscience
Ark Therapeutics Group ArQule
Array BioPharma Arrowhead Research Corporation
Ascendis Pharma ASIT biotech
ASLAN Pharmaceuticals Astex Pharmaceuticals
Athersys Atossa Genetics
Auris Medical Holding Avacta Group
Avalanche Biotechnologies AVEO Pharmaceuticals
Avita Medical Avivagen
Balda Basilea Pharmaceutica
Bavarian Nordic Bellus Health
Benitec Biopharma BioCryst Pharmaceuticals
BioInvent BioLargo
BioLight Life Sciences BioLineRx
BiondVax Pharmaceuticals Bionomics
Bionor Pharma BioPorto Diagnostics
Biota Holdings Biotie Therapies Corp
Biotron Bluebird Bio
Bone Therapeutics Bonesupport
BrainStorm Cell Therapeutics Brighter
BTG C4X Discovery Holdings
Caladrius Biosciences Can-Fite BioPharma
CannTrust Holdings Cantargia
Capstone Therapeutics Carmat
CASI Pharmaceuticals Cell Therapy
Celldex Therapeutics Cellectis
Cellular Biomedicine Group Celyad
Cerulean Pharma Circadian Technologies
Circassia Pharmaceuticals Clal Biotechnology Industries
Clavis Pharma Cleveland BioLabs
Clinigen Group Clinuvel
CO.DON CollPlant Holdings
Consort Medical Corium International
Crescendo Crossject
CSL Curetis NV
Curis Cytori Therapeutics
Cytos Biotechnology CytRx Corporation
DBV Technologies Dechra Pharmaceuticals
Deinove Delcath Systems
Deltex Medical Derma Sciences
Destiny Pharma DiaSorin
Diaxonhit e-Therapeutics
Egalet Corporation EKF Diagnostics
Elbit Medical Technologies Ellex Medical Lasers
Emergent BioSolutions Endocyte
Epigenomics Ergomed
Erytech Pharma Esperion Therapeutics
Evotec Exact Sciences
Exelixis Expedeon
EyeGate Pharmaceuticals Factor Therapeutics
Formycon Forward Pharma
Fresenius SE & Co. KGaA Futura Medical
Galapagos Galmed Pharmaceuticals
Genedrive Genfit
Genkyotex Genmab
GeoVax GI Dynamics
Gilead Sciences GNI Group Ltd
GW Pharmaceuticals Halozyme Therapeutics
Heat Biologics Inc. Heidelberg Pharma
Herantis Pharma Horizon Discovery
Hutchison China MediTech Hybrigenics
iCo Therapeutics Idenix
Immune Pharmaceuticals Immunicum
Immunodiagnostic Systems Holdings Immunovia
ImmuPharma Immutep
Imprimis Pharmaceuticals Imugene
Incyte Corporation Infinity Pharmaceuticals
InflaRx InMed Pharmaceuticals
Innate Pharma Insmed
Intec Pharma International Stem Cell
Invion Ion Beam Applications
Ipsogen Iridex
Ironwood Pharmaceuticals Islet Sciences
Ixico Japan Tobacco
KaloBios Pharmaceuticals Kane Biotech
Karolinska Development Kazia Therapeutics
Keryx Biopharmaceuticals Kiadis Pharma
Laboratorios Farmacéuticos ROVI LCA-Vision
LeMaitre Vascular Lifeline Scientific
LifeWatch Ligand Pharmaceuticals
Lipocine Lombard Medical Technologies
MagForce Mast Therapeutics
Medcom Tech Medicago
MediciNova Medicure
Medigene MedinCell
Medivir Merrimack Pharmaceuticals
Merrion Pharmaceuticals Mesoblast
MethylGene MGC Pharmaceuticals
Midatech Pharma MISSION Therapeutics
Molecular Partners MolMed
Mologen Momenta Pharmaceuticals
MorphoSys Nanobiotix
Nanosonics Navidea Biopharmaceuticals
Nektar Therapeutics NeoStem
Neovacs NetScientific
NeuroVive Pharmaceutical Newron Pharmaceuticals
Nexstim NicOx
NMC Health NorDiag
Nordion NovaBay Pharmaceuticals
Novacyt NPS Pharmaceuticals
Nuevolution Ocata Therapeutics
Omega Diagnostics Group Omeros Corporation
OncoGenex Pharmaceuticals Oncology Venture
Oncolytics Biotech Inc OncoMed Pharmaceuticals
Onconova Therapeutics Oncothyreon
Onxeo Onyx Pharmaceuticals
Opexa Therapeutics OPMEDIC Group
Optos Orexigen Therapeutics
Orexo Orgenesis
Oryzon Genomics OSE Immunotherapeutics
Ossur OvaScience
OWL Oxford BioMedica
Oxford Immunotec Pacific Edge
Paion Paladin Labs
Patheon PBKM
PDL BioPharma Pharmacyclics
PharmaMar Pharmaxis
Pharming Group Photocure
Phylogica Pixium Vision
Pluristem Therapeutics Prescient Therapeutics
Probiodrug ProMetic Life Sciences
Prosensa Proteome Sciences
PsiOxus QRxPharma
Quantum Genomics Quantum Pharmaceuticals
Race Oncology Regeneus
Relmada Therapeutics ReNeuron Group
Resverlogix REVA Medical
Rovi RXi Pharmaceuticals
Sangamo BioSciences Sarepta Therapeutics
Sartorius Scancell
Selvita Shield Therapeutics
Shire Sierra Oncology
Silence Therapeutics Simavita
Sinclair Pharma Sirtex Medical
Skyepharma Smith & Nephew
Sobi Sosei Group Corporation
Source Bioscience SQI Diagnostics
Stallergenes StemCells
Stentys Stratec Biomedical
Sucampo Pharmaceuticals Sunesis Pharmaceuticals
Surgical Innovations Sygnis
SymBio Pharmaceuticals Synairgen
Synergy Health Synta Pharmaceuticals
T‐cell cancer therapies Targovax
TearLab Corp Tekmira
Telix Pharmaceuticals TESARO
Theraclion Therapix Biosciences
Threshold Pharmaceuticals ThromboGenics
TiGenix Tissue Regenix
Tissue Therapies Titan Pharmaceuticals
Tonix Pharmaceuticals Topotarget
Touchstone Innovations Transgene
Trillium Therapeutics True Leaf
TruScreen TxCell
UCB UDG Healthcare
uniQure NV Universal Biosensors
VBI Vaccines Vectura
Verastem Verisante Technology
Vernalis Verona Pharma
Vertex Pharmaceuticals Viralytics
ViroPharma Vivalis
Vivus VolitionRx
WaferGen Biosystems Xbrane Biopharma
Xencor Zafgen
Zealand Pharma Ziopharm Oncology

Company news

RedHill Biopharma Ltd. ADR

Sun, 27 Mar 2016 01:50:36 GMT

Exclusive: RedHill Biopharma CEO Talks Steering His Company Through A Year ...

Mon, 05 Jun 2017 19:56:44 GMT

Valeant Pharmaceuticals Intl Inc (VRX) Keeps Fighting to Turnaround Debt ...

Tue, 03 Oct 2017 18:48:38 GMT

RedHill Biopharma reports positive results from mid-stage trial of irritable ...

Tue, 03 Oct 2017 11:03:45 GMT

IntelGenx Technologies Corp. (OTCMKTS:IGXT) and RedHill Biopharma Ltd – ADR ...

Thu, 02 Oct 2014 13:24:07 GMT

Y/E Dec Revenue (US$m) EBITDA (US$m) PBT (US$m) EPS (c) P/E (x) P/CF (x)
2016A 0.1 (30.5) (29.4) (22.85) N/A N/A
2017A 4.0 (51.9) (45.5) (25.99) N/A N/A
2018E 9.5 (39.9) (40.0) (16.14) N/A N/A
2019E 12.4 (41.6) (41.7) (14.71) N/A N/A

Last updated on 19/12/2018

Latest research

המחקר העדכני ביותר

רדהיל ביופארמה

RedHill Biopharma:לפני סוף השנה TALICIA עם IIIתוצאות מניסוישלב

02/10/2018
רדהיל ביופארמה

RedHill Biopharma: םיניוצמ םיארנ RHB-104 ינותנ

08/08/2018
רדהיל ביופארמה

RedHill Biopharma: ,)GI( לוכיעה יכרד ירצומ לש תוריכמ תחימצ ךשמה םישדח 3 -כ דועב ןהורקב III בלש יוסינ תואצות

24/05/2018
רדהיל ביופארמה

מו"פ הממוקד בתרופות גסטרו מגיע לשלב המסחרי

29/03/2018
רדהיל ביופארמה

IBS-D- ל BEKINDA ניסוי שלב 2 מוצלח עם

27/11/2017
רדהיל ביופארמה

RedHill Biopharma- חברת תרופות בעלת זרזים פיננסיים עתידיים רבים

24/11/2016

Investment summary

RedHill has a broad R&D pipeline, but is focusing on GI and inflammatory diseases. The most advanced assets are TALICIA (RHB-105) for H. pylori infection (positive top-line results from confirmatory Phase III announced December 2018); RHB-104 for Crohn’s disease (positive top-line results from first Phase III announced July 2018); BEKINDA for both gastroenteritis (positive results from first Phase III announced June 2017) and IBS-D (positive final Phase II results announced January 2018); and RHB-204 for pulmonary non-tuberculous mycobacteria infections (pivotal Phase III trial to start mid-2019). RedHill promotes four GI products in the US (Donnatal, EnteraGam, Esomeprazole Strontium DR Capsules 49.3mg and Mytesi). Q318 net revenues were $2.2m and cash position was $43m as of 30 September 2018.

Last updated on 01/02/2019

Industry outlook

RedHill's main focus on GI and inflammation include a range of conditions, which although can be treated with a variety of innovative and established products, there is still an unmet need in each of the diseases. In our view, carefully positioned, innovative solutions for the patients will attract attention.

Last updated on 01/02/2019

Key management

Dror Ben-Asher, CEO
Micha Ben Chorin, CFO
Gilead Raday, Chief Operating Officer
Guy Goldberg, Chief Commercial Officer

Company address

21 Ha’arba’a St.
Tel-Aviv
6473921
Israel
+972-(0)3-541-3131
View website